-
Mashup Score: 1Press Releases | Kite Pharma - 1 year(s) ago
Find recent Kite press releases here.
Source: www.kitepharma.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma - 1 year(s) ago
PURPOSE Chemoimmunotherapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) is largely unchanged for decades. Both preclinical models and clinical data suggest the combination of lenalidomide and ibrutinib may have synergy in DLBCL, particularly in the non–germinal center B-cell-like subset. METHODS We enrolled 60 patients with newly diagnosed non–germinal center…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
It is so gratifying to share the final manuscript with patients who are in a long term remission from a clinical trial we created. #lymsm #EndCancer https://t.co/buX7Lvm7Up
-
-
Mashup Score: 0ASCO Election - 2 year(s) ago
ASCO Election
Source: ASCOCategories: Hem/Oncs, Latest HeadlinesTweet-
The election for @ASCO leadership is open to all members. It takes a ~1 minute to vote for these outstanding volunteer leader nominees, and is so important. https://t.co/YEyXVOlz69
-
-
Mashup Score: 7
A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet-
We’re proud to present our poster at #SOHO22 on the LOTIS-9 trial. R-LoncaT in unit/frail patients with newly diagnosed large B-cell lymphoma. Open and recruiting now. https://t.co/qa8zwZoFRx #lymsm https://t.co/TQQqi1m7fq
-
-
Mashup Score: 0Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma - 2 year(s) ago
PURPOSE Chemoimmunotherapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) is largely unchanged for decades. Both preclinical models and clinical data suggest the combination of lenalidomide and ibrutinib may have synergy in DLBCL, particularly in the non–germinal center B-cell-like subset. METHODS We enrolled 60 patients with newly diagnosed non–germinal center…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
The full manuscript: https://t.co/z2k7J5auM6
-
-
Mashup Score: 0
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet-
The next step trial where we reduce/remove chemo based upon response: https://t.co/12HBOZRLmu
-
-
Mashup Score: 3Uterine Cancer Is on the Rise, Especially Among Black Women - 2 year(s) ago
The cancer eventually will become the third most common type among women, experts say. The mortality rate is highest among Black Americans.
Source: www.nytimes.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Important article in @nytimes about rising rates of #UterineCancer, with a quote from @ShannonWestin from @MDAndersonNews https://t.co/QvXRBYtEs1
-
-
Mashup Score: 3Lymphoma/Myeloma Fellowship - 2 year(s) ago
The goals of the Lymphoma/Myeloma Fellowship program are to train Fellows to provide specialized care for patients with Hodgkin disease, non-Hodgkin lymphoma and multiple myeloma; to successfully design and implement clinical research studies; and to be in a position to conduct independent research in lymphoma/myeloma and apply for research funding. Through a combination of inpatient and…
Source: MD Anderson Cancer CenterCategories: Hem/Oncs, Latest HeadlinesTweet-
We are proud to announce the MD Anderson Lymphoma & Myeloma Fellowship program, better than ever. If you are interested, see details here: https://t.co/WHVbiK7L9G
-
-
Mashup Score: 2Keith Stewart, MBChB, MBA, Discusses the Career Critics - 2 year(s) ago
For those who choose the path of manufactured controversy or divisive rhetoric …, “What exactly have you contributed?”
Source: bloodcancerstoday.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Excellent analysis by @akeithstewart on the social media creature: the critic without contributions https://t.co/laM0aCqrMn
-
-
Mashup Score: 0Lymphoma Daily - 2 year(s) ago
Content directly from sources and does not necessarily reflect my views by Jason R Westin
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest Lymphoma Daily! https://t.co/IQOYL7ogu2 Thanks to @AaronGoodman33 @knowyournodes @JeromeCoutet #lymphoma #nonhodgkinslymphoma
-
We now know that ZUMA7 has a statistically significant improvement in overall survival. This is the first improvement in OS in second-line therapy in nearly 30 years. https://t.co/vwrgP9lmVv